



Scientific Programme

Monday, 21 September 2015

	Workshops and Courses, Room 2
09:00 - 10:00	Career Workshop with Peggy McKee I
09:00 - 10:00	Resumes - 3 Simple Changes to Get More Interviews P. McKee (Career Confidential, Gunter, United States)
	Workshops and Courses, Room 3
09:30 - 17:00	6th SiLA Conference: Device & Data Standards: Leaving More Time for Innovation Y. Hofmann (Xavo Systems AG / Association Consortium Standardization in Lab Automation (SiLA), Rapperswil, Switzerland)
09:30 - 09:50	Welcome Coffee
09:50 - 10:00	Welcome P. Schleiffer (Association Consortium Standardization in Lab Automation (SiLA), Rapperswil, Switzerland)
10:00 - 10:45	Keynote Lecture: 15 Years of OME: Open Image Informatics for the Biological and Biomedical Sciences J. Swedlow (Open Microscopy Environment, Dundee, United Kingdom)
10:45 - 11:00	Lab of the Future? - SiLA is Key! D. Juchli (wega Informatik AG, Basel, Switzerland)
11:00 - 11:15	Closing the gap between R&D and QC, Process Management Systems and Applicable Standards M. Fish (Brooks Life Science Systems, Warrington, United Kingdom)
11:15 - 11:30	SiLA PMS as an enabling technology to maintain quality and manage variability in cell culture applications T. Frech (Xavo Systems AG, Reinach, Switzerland)
11:30 - 11:45	Compliant Laboratory Automation Made Easy with SiLA & the apartis Scheduler K. Gerhold (apartis Information Management, Bingen am Rhein, Germany)
11:45 - 12:00	Partners, Projects, & Projections of SiLA D. Johnston (Association Consortium Standardization in Lab Automation (SiLA), Rapperswil, Switzerland)
12:00 - 12:15	Connecting the Laboratory Media Bottle with the Future M. Merz (DURAN Group GmbH, Wertheim/Main, Germany)
12:15 - 13:15	Lunch Break



Scientific Programme

13:15 - 13:45	<p>SiLA Announcement Y. Hofmann (Xavo Systems AG / Association Consortium Standardization in Lab Automation (SiLA), Rapperswil, Switzerland)</p>
13:45 - 14:00	<p>How to Get a Simple, Expandable, & Reproducible Robot Platform That Fits in Every Lab (and Budget!) O. Peter (Actelion Pharmaceuticals Ltd., Allschwil, Switzerland)</p>
14:00 - 14:15	<p>Integrated Data in Automated Workflows - No Longer a Luxury A. Brendel (infoteam Software AG, Stäfa, Switzerland)</p>
14:15 - 14:30	<p>SiLA Integration in INSTINCT V & the Hurdles F. Brehm (Hamilton Company, Bonaduz, Switzerland)</p>
14:30 - 14:45	<p>Title to be confirmed A. Wechsler (Fraunhofer-IPA, Stuttgart, Germany)</p>
14:45 - 15:00	<p>Handling Robot - Integration with SiLA Server - Experience & Future Vision R. Schelbert (Credimex AG, Alpnach, Switzerland)</p>
15:00 - 15:30	<p>Coffee Break</p>
15:30 - 15:45	<p>News from SiLA: SiLA Data Standard-AnIML B. Schäfer (BSSN Software GmbH, Darmstadt, Germany)</p>
15:45 - 16:00	<p>News from SiLA: SiLA DCDIS/Command Dictionary Specification B. Papenfuss (EQUIcon Software GmbH Jena, Jena, Germany)</p>
16:00 - 16:15	<p>News from SiLA: SiLA Process Management System T. Frech (Xavo Systems AG, Reinach, Switzerland)</p>
16:15 - 16:30	<p>News from SiLA: SiLA Pipettor Standard S. Angele (infoteam Software AG, Stäfa, Switzerland)</p>
16:30 - 16:45	<p>News from SiLA: SiLA Certification Standard/Pilot Test Initiative A. Wechsler (Fraunhofer-IPA, Stuttgart, Germany)</p>
16:45 - 17:00	<p>News from SiLA: SiLA Open Source Initiative D. Juchli (wega Informatik AG, Basel, Switzerland)</p>
	Workshops and Courses, Room 2
10:15 - 11:15	<p>Career Workshop with Peggy McKee II</p>
10:15 - 11:15	<p>Job Search Solutions - Where Are the Hidden Jobs? P. McKee (Career Confidential, Gunter, United States)</p>
	Workshops and Courses, Room 2
11:30 - 12:30	<p>Career Workshop with Peggy McKee III</p>



Scientific Programme

11:30 - 12:30

Job Interviews - How to Get More Offer

P. McKee (Career Confidential, Gunter, United States)

13:30 - 14:30

Workshops and Courses, Room 2

Career Workshop with Peggy McKee IV

13:30 - 14:30

How to Get a Promotion

P. McKee (Career Confidential, Gunter, United States)

14:45 - 15:45

Workshops and Courses, Room 2

Career Workshop with Peggy McKee V

14:45 - 15:45

Older Job Seekers - What You Need to Know About Age and Your Job Search

P. McKee (Career Confidential, Gunter, United States)



Scientific Programme

Tuesday, 22 September 2015

	Scientific Forum, Room 1
08:30 - 12:00	Peptide Therapeutics T. Vorherr (Novartis Pharma AG, Basel, Switzerland) E. Kitas (Roche Innovation Center, Basel, Switzerland) R. Stocklin (Atheris SA, Geneva, Switzerland)
08:30 - 09:30	Peptides as molecular interactors E. Giralt (Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain)
09:30 - 10:00	Coffee Break
10:00 - 10:30	(Glyco)Protein ligation enabled by the controlled cleavage of peptide bonds D. Macmillan (University College London, London, United Kingdom)
10:30 - 11:00	Laser-printed high density peptide microarrays for peptide target binder discovery and optimization V. Stadler (Pepperprint GmbH, Heidelberg, Germany)
11:00 - 11:30	Phage selection of bicyclic peptides for application as therapeutics C. Heinis (EPFL, Lausanne, Switzerland)
11:30 - 12:00	Tumor-penetrating peptides in the targeting of drugs and theranostic nanoparticles T. Teesalu (Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia)
	Scientific Forum, Room 2
08:30 - 12:00	Digital Health & Care B. Hofrichter (ConCeplus GmbH, Weggis, Switzerland) P. Dümmler (Switzerland)
08:30 - 08:40	Intro / Welcome B. Hofrichter (ConCeplus GmbH, Weggis, Switzerland)
08:40 - 09:00	An outlook on digital health & care by 2030 B. Hofrichter (ConCeplus GmbH, Weggis, Switzerland) T. Wilckens (Innventis, Munich, Germany)
09:00 - 09:30	Will ICT stimulate optimization of healthcare value chains globally? R. Herzog (HiMSS Europe, Berlin, Germany)
09:30 - 10:00	Personalized Medicine - Future trends & developments R. Barker (Precision Medicine Catapult, Innovate UK, Swindon, United Kingdom)
10:00 - 10:30	Coffee Break



Scientific Programme

10:30 - 10:50		<p>Present & future of healthcare portals: Advancing healthcare towards 2030?</p> <p>M.E. Petersen (Sundhed, Copenhagen, Denmark)</p>
10:50 - 11:10		<p>How digital technologies will revolutionize pharmaceutical clinical trials</p> <p>A. Brown (Novartis Pharma AG, Basel, Switzerland)</p>
11:10 - 12:00		<p>Panel discussion forum digital health & care - represent data ethics for medical data and necessary technical considerations</p> <p>D. Selz (Squirro AG, Zurich, Switzerland) R. Barker (Precision Medicine Catapult, Innovate UK, Swindon, United Kingdom) M.E. Petersen (Sundhed, Copenhagen, Denmark) A. Brown (Novartis Pharma AG, Basel, Switzerland) C. Biermann (Diaverum Group, Munich, Germany) E. Georgiew (SEMASU Ltd., Eching, Germany) R. Herzog (HiMSS Europe, Berlin, Germany) T. Wilckens (Innventis, Munich, Germany)</p>
		<p>Scientific Forum, Room 5</p>
08:30 - 12:00		<p>Drug Discovery Sciences SLAS</p> <p>C. Fattinger (Roche Innovation Center, Basel, Switzerland) G. Cutler (Novartis Pharma AG, Basel, Switzerland)</p>
08:30 - 09:00		<p>Droplet interface Bilayers: new tools for ion-channel screening</p> <p>M. Wallace (University of Oxford, Oxford, United Kingdom)</p>
09:00 - 09:30		<p>Micro-nano opportunities in bioanalytics: molography, plasmonic particle based single cell analytics, and miniaturized immunofiltration</p> <p>J. Voeroes (ETH Zurich, Zurich, Switzerland)</p>
09:30 - 10:00		<p>Cell-based high-content screening with label-free Digital Holographic Imaging</p> <p>B. Rappaz (EPFL Lausanne, Lausanne, Switzerland)</p>
10:00 - 10:30		<p>Coffee Break</p>
10:30 - 11:00		<p>Drug discovery using kinetic live cell imaging of primary human cells</p> <p>E. Schmidt (Novartis Pharma AG, Basel, Switzerland)</p>
11:00 - 11:30		<p>Phenotypic Drug Discovery: discovering medicine based on disease biomarkers</p> <p>M. Prunotto (Roche Innovation Center, Basel, Switzerland)</p>
11:30 - 12:00	P130	<p>Combination of flow cytometry-based phenotypic screening and smart compound selection for rapid identification of novel cell cycle inhibitors</p> <p>L. Brault (Exquiron Biotech AG, Reinach, Switzerland)</p>



Scientific Programme

		Scientific Forum, Room 3
08:45 - 12:00		Synergy Forum G. Ulrich-Merzenich (University Clinic Bonn, Bonn, Germany) D. Simeon-Dubach (medservice, Wachwil, Switzerland)
08:45 - 09:00		Introduction G. Ulrich-Merzenich (University Clinic Bonn, Bonn, Germany) D. Simeon-Dubach (medservice, Wachwil, Switzerland)
09:00 - 09:30		Pharmacokinetic profiling for discovering synergies and antagonism of herbs and drugs V. Butterweck (University of Applied Sciences Northwestern Switzerland, Muttenz, Switzerland)
09:30 - 10:00		From Additivity to Synergism C. Ritz (University of Copenhagen, Frederiksberg, Denmark)
10:00 - 10:30		Coffee Break
10:30 - 11:00		Exploring & quantifying compound combinations in high throughput settings: going beyond 1D metrics R. Guha (National Center for Advancing Translational Sciences, Bethesda, United States)
11:00 - 11:15	P200	Screening of synergic interactions of anti-angiogenic and anti-tumor compounds M.Á. Medina (Universidad de Málaga, Málaga, Spain)
11:15 - 11:30	P202	Gene expression profiling as a promising approach for justifying fixed drug combination products O. Kelber (Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany)
11:30 - 12:00		System modeling of intra-tumor heterogeneity for the development of novel combination therapies J.-P. Abbuehl (Ecole Polytechnique federale de Lausanne, Lausanne, Switzerland)
		Education Forum, Room 4
09:00 - 12:00		Jumpstarting Innovation S. Emmerth (iNet Innovation Networks Switzerland, Basel, Switzerland) A. Moeri (Swiss Innovation Park NWCH, Basel, Switzerland) B. Bhullar (Novartis Pharma AG, Basel, Switzerland) C. Kloepper (iNet Innovation Networks Switzerland, Basel, Switzerland)
09:00 - 09:15		Welcome and Introduction B. Bhullar (Novartis Pharma AG, Basel, Switzerland) S. Emmerth (iNet Innovation Networks Switzerland, Basel, Switzerland)
09:15 - 09:30		Swiss Innovation Park: An Introduction A. Moeri (Swiss Innovation Park NWCH, Basel, Switzerland)
09:30 - 10:00		Creating Rare Disease Companies C. Adams (Cydan Development, Cambridge, United States)



Scientific Programme

10:00 - 10:30	Coffee Break
10:30 - 11:00	Building biotech startups with Novo Seeds as investor S. Møller (Novo Seeds, Hellerup, Denmark)
11:00 - 11:30	Breakout Labs: Catalyzing groundbreaking science out of the laboratory and into the economy H. Parthasarathy (Breakout Labs, San Francisco, United States)
11:30 - 12:00	Q&A
10:00 - 17:00	Vendor Exhibition, Hall 4.1 Vendor and Poster Exhibition
12:30 - 13:30	Industry Symposium, Room 1 Shared Innovation in Drug Discovery: European Lead Factory Are you looking for an opportunity to screen your promising drug target against a world-class compound library at no upfront costs? Do not miss our symposium! The European Lead Factory is an open-innovation platform for drug discovery supported by the Innovative Medicines Initiative (IMI). It provides academics and SMEs with access to state-of-the-art facilities for hit identification. Attend the symposium for information about the European Lead Factory concept and capabilities, learn from a scientist who has preceded you and get all your questions answered by our panel of experts.
12:30 - 13:30	Shared Innovation in Drug Discovery: European Lead Factory J. De Vlieger (TI Pharma, Leiden, Netherlands) H. Rutjes (Pivot Park Screening Centre, Oss, Netherlands) M. Mahlapuu (University of Gothenburg, Gothenburg, Sweden)
12:30 - 13:30	Workshops and Courses, Room 2 Career Workshop with Peggy McKee VI
12:30 - 13:30	Networking for Career Success P. McKee (Career Confidential, Gunter, United States)



Scientific Programme

12:30 - 13:30

Industry Symposium, Room 3

Industry Symposium: Making the Jump - How to Start Business in the USA

“Making the Jump” hosted by BIO-Jump and the US Embassy, will be an interactive lunch symposium about the obstacles and opportunities for European Life Science companies to develop a business in the USA.

European Biotechs will share experiences they made with authorities, customs and customers when they established their US subsidiary.

BIO-Jump and Choose New Jersey will represent US institutions which provide support and solutions for international companies doing business within the United States. After the speakers have given their insight into the topic the session will conclude with a podium discussion on the biggest challenges and chances. Light lunch will be provided.

Making the Jump - How to Start Business in the USA

S. LeVine (US Embassy, Berne, Switzerland)
 J. Lichtenberg (InSphero AG, Schlieren, Switzerland)
 F. von Haniel (Axiogenesis AG, Cologne, Germany)
 M. Henderson (Choose New Jersey, Inc., Princeton, United States)
 A.R. Kark (BIO-jump, LLC, Hillsborough, United States)

12:30 - 13:30

Industry Symposium, Room 4

Industry Symposium: Reporter Bioassays for Immunotherapy Programs - Promega

Immunotherapy is now center stage. Immune checkpoint inhibitors and activators are the hottest drug targets. Key inhibitor drugs in the market such as anti-Programmed cell Death protein 1 PD-1 antibodies nivolumab (Opdivo), lambrolizumab (Keytruda), and ipilimumab (Yervoy, an anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) antibody) are providing long-term benefits to cancer patients. Traditional inhibitory blockade studies commonly use animal models or freshly isolated peripheral blood mononuclear cells (PBMCs) to quantify antibody drug biological activity. Here we demonstrate multiple bioluminescent reporter-based assays that can be used to rapidly measure potencies of multiple biological immunotherapy drugs. We also demonstrate that these bioassays reflect mode of action of each drug, and quantify potencies of on-market monoclonal antibody drugs for cancer.

12:30 - 13:30

Reporter bioassays to assess therapeutic antibodies in development for immunotherapy programs

M. Cong (Promega Corporation, Madison, United States)

13:30 - 14:20

Keynote, Room 5

Welcome Words / Keynote Lecture 1 J.-P. Clozel, Actelion

Welcome Words

B. Bhullar (Novartis Pharma AG, Basel, Switzerland)



Scientific Programme

From a start-up to a middle sized biopharmaceutical company: what did I learn?

J.-P. Clozel (Actelion Pharmaceuticals Ltd., Allschwil, Switzerland)

Scientific Forum, Room 1

14:30 - 17:00

Peptide Therapeutics

T. Vorherr (Novartis Pharma AG, Basel, Switzerland)
E. Kitas (Roche Innovation Center, Basel, Switzerland)
R. Stocklin (Atheris SA, Geneva, Switzerland)

14:30 - 15:00

Computational tools for predicting the permeability of peptides

M. Schaefer (Novartis Pharma AG, Basel, Switzerland)

15:00 - 15:30

Uncovering the principles that drive passive membrane permeability in meso-MW compounds: Tackling a rich chemical space with new and used paradigms

S. Lokey (University of California Santa Cruz, Santa Cruz, United States)

15:30 - 16:00

Coffee Break

16:00 - 16:30

Cellular peptide entry - induced versus constitutive permeability

R. Brock (Radboud University Medical Centre, Nijmegen, Netherlands)

16:30 - 17:00

Sequence-defined oligomers containing natural and artificial oligo-amino acids for intracellular drug, protein and nucleic acid delivery

E. Wagner (Ludwig-Maximilian University Munich, Munich, Germany)

Scientific Forum, Room 3

14:30 - 17:00

Synergy Forum

G. Ulrich-Merzenich (University Clinic Bonn, Bonn, Germany)
D. Simeon-Dubach (medservice, Wachwil, Switzerland)

14:30 - 15:00

The antitumor potential of the endocannabinoid-reuptake inhibitor OMDM-2 alone and in combination with cytostatic drugs

R. Ammar (Kairo University, Kairo, Egypt)

15:00 - 15:15

P201

Synergism research: a tool for the study of pharmacology and toxicology of herbal medicinal products

O. Kelber (Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany)

15:15 - 15:30

P260

Evaluation of combination treatment efficacy utilizing the Labcyte Echo® liquid handler and Echo® combination screen software with reduced cost, increased throughput and flexibility in an MCF-7 viability assay

15:30 - 16:00

Coffee Break

16:00 - 16:15

Drug regulatory aspects for combination treatments: regulatory and industrial perspective

H. Schweim (University of Bonn, Bonn, Germany)



Scientific Programme

16:15 - 16:30		Drug regulatory aspects of combination treatments - requirements for the authorization from an industrial perspective I. Radtke (Roche, Basel, Switzerland)
16:30 - 17:00		Panel Discussion Education Forum, Room 4
14:30 - 16:30		Jumpstarting Innovation S. Emmerth (iNet Innovation Networks Switzerland, Basel, Switzerland) A. Moeri (Swiss Innovation Park NWCH, Basel, Switzerland) B. Bhullar (Novartis Pharma AG, Basel, Switzerland) C. Kloeppe (iNet Innovation Networks Switzerland, Basel, Switzerland)
14:30 - 15:00		Engaging public-private partnerships to transform academic innovations into the drugs of tomorrow P. Walker (NEOMED, Canada)
15:00 - 15:30		Allied Minds: Transforming Invention into Innovation M. Pritchard (Allied Minds, Boston, United States)
15:30 - 16:00		Novel ways to identify & nurture healthcare innovation K. Hertogs (Johnson & Johnson Innovation, London, United Kingdom)
16:00 - 16:30		Patient-driven ALS drug development - innovation by collaboration I. de Greef-van der Sandt (Treeway, Rotterdam, Netherlands) B. Müller (Treeway, Rotterdam, Netherlands)
		Scientific Forum, Room 5
14:30 - 17:00		Drug Discovery Sciences SLAS C. Fattinger (Roche Innovation Center, Basel, Switzerland) G. Cutler (Novartis Pharma AG, Basel, Switzerland)
14:30 - 15:00		Development of a high throughput acoustic loading system for mass spectrometry J. Wingfield (AstraZeneca, Cambridge, United Kingdom)
15:00 - 15:30	P150	Binding studies of type I, II, and III kinase inhibitors against Bcr-Abl kinase using back-scattering interferometry: a tale of allostery R.R. Lavieri (Molecular Sensing Inc., Los Gatos, United States)
15:30 - 16:00		Advancing the CRISPR/Cas9 technology platform for therapeutic application V. Myer (Editas Medicine, Cambridge, United States)
16:00 - 16:30		Coffee Break
16:30 - 17:00	P140	High fidelity small molecule DNA-encoded yoctoreactor libraries L.K. Petersen (Vipergen ApS, Copenhagen, Denmark)



Scientific Programme

17:15 - 18:00	Keynote, Room 5 Innovation Keynote Lecture - Robert Hariri, Human Longevity Cellular Therapeutics B. Bhullar (Novartis Pharma AG, Basel, Switzerland) C. Kloepper (iNet Innovation Networks Switzerland, Basel, Switzerland)
17:15 - 18:00	The Value of Medical Innovation R. Hariri (Human Longevity, San Diego, United States)
18:00 - 19:00	Welcome Reception, Hall 4.1 Welcome Reception



Scientific Programme

Wednesday, 23 September 2015

	Scientific Forum, Room 1
08:30 - 12:00	Peptide Therapeutics T. Vorherr (Novartis Pharma AG, Basel, Switzerland) E. Kitas (Roche Innovation Center, Basel, Switzerland) R. Stocklin (Atheris SA, Geneva, Switzerland)
08:30 - 09:30	Enhanced Paracellular Transport of Insulin Can Be Achieve Via Transient Induction of Myosin Light Chain Phosphorylation R. Mrsny (University of Bath, Bath, United Kingdom)
09:30 - 10:00	Coffee Break
10:00 - 10:30	Structure-guided optimization and design of a novel peptidomimetic scaffold: discovery of novel small-molecule adenain inhibitors E. Altmann (Novartis Pharma AG, Basel, Switzerland)
10:30 - 11:00	Cargo delivery into the brain by in vivo identified transport peptides E. Urich (Fa.Hoffmann-LaRoche, Basel, Switzerland)
11:00 - 11:30	Drug delivery and release systems for targeted tumor therapy A. Beck-Sickinger (University of Leipzig, Leipzig, Germany)
11:30 - 12:00	Tailoring semisynthetic ligands to investigate and regulate ErbB receptor family dysregulation in cancer C. Kroll (F. Hoffmann La-Roche, Basel, Switzerland)
	Scientific Forum, Room 5
08:45 - 12:00	Next Generation Sequencing C. Mason (Cornell University, New York, United States) J. Dudley (Icahn School of Medicine at Mount Sinai, New York, United States) B. Bhullar (Novartis Pharma AG, Basel, Switzerland)
08:45 - 09:00	Introduction C. Mason (Cornell University, New York, United States) B. Bhullar (Novartis Pharma AG, Basel, Switzerland)
09:00 - 09:30	Integrating Genotype Protocols into Disease Management C. DesRosiers (CareMed Pharmaceutical Services, Lake Success, United States)
09:30 - 10:00	NGS and Drug Safety Prediction N. Tatonetti (Columbia School of Medicine, New York, United States)
10:00 - 10:30	Coffee Break
10:30 - 11:00	The signature program - a novel trial model for rapid signal finding studies in a molecularly pre-selected patient population B. Kang (Novartis Pharma AG, East Hanover, United States)



Scientific Programme

11:00 - 11:30

Bioinformatics solutions for 100,000 genomes

A. Rendon (Genomics England Ltd., London, United Kingdom)

11:30 - 12:00

Meeting the challenge of DNA data storage and security

D. Fortune (Baseport, Calgary, Canada)

Scientific Forum, Room 2

09:00 - 12:00

Stem Cells in Biomedicine

R. Heilker (Boehringer Ingelheim, Biberach, Germany)
 C. Cusulin (Roche Innovation Center, Basel, Switzerland)
 C. Hippert (Roche Innovation Center, Basel, Switzerland)

09:00 - 09:30

Human pluripotent stem cells for cardiac disease modeling and safety pharmacology

R. Passier (Leiden University Medical Center, Leiden, Netherlands)

09:30 - 10:00

Harnessing human pluripotent stem cells for drug discovery in monogenic diseases

M. Peschanski (iStem, Evry Cedex, France)

10:00 - 10:30

Coffee Break

10:30 - 11:00

Generation of humanized models for the understanding of Health and Aging

M. Kraus (Nestle institute of Health Sciences, Lausanne, Switzerland)

11:00 - 11:30

iPSC-based approaches to model and treat neurodegenerative diseases

J. Schwamborn (University of Luxembourg, Esch-sur-Alzette, Luxembourg)

11:30 - 12:00

Retinal repair through transplantation of ES cell-derived photoreceptors

R. Ali (University College London, London, United Kingdom)

Scientific Forum, Room 4

09:00 - 12:00

Infectious Diseases

D. Ritz (Actelion Pharmaceuticals Ltd., Allschwil, Switzerland)
 U. Jenal (University of Basel, Basel, Switzerland)
 G. Dernick (Roche Innovation Center, Basel, Switzerland)

09:00 - 09:30

Evolution and epidemiology of multidrug-resistant tuberculosis

S. Gagneux (Swiss TPH, Basel, Switzerland)

09:30 - 10:00

Bacterial antimicrobial resistance: an evolutionary perspective

J. Rolff (Free University Berlin, Berlin, Germany)

10:00 - 10:30

Coffee Break

10:30 - 11:00

Novel topoisomerase inhibitors active on Gram negative bacteria

C. Zumbunn (Actelion Pharmaceuticals Ltd, Allschwil, Switzerland)



Scientific Programme

11:00 - 11:30		Antimicrobial peptide prodrugs activated by neutrophil elastase M. Devocelle (Royal College of Surgeons in Ireland, Dublin, Ireland)
11:30 - 12:00		Anti-adhesion therapy to prevent urinary tract infections B. Ernst (University of Basel, Basel, Switzerland)
		Scientific Forum, Room 3
09:15 - 12:00		Medicinal Chemistry J. Harris (cjh consultants, Eynsford, United Kingdom) A. Hersey (EMBL-EBI, Hinxton, United Kingdom)
09:15 - 09:30		Introduction J. Harris (cjh consultants, Eynsford, United Kingdom) A. Hersey (EMBL-EBI, Hinxton, United Kingdom)
09:30 - 10:00		Sharing pharma compounds with academia: experiences with providing vitamin D receptor ligands S. Hackethal (Charite Berlin, Berlin, Germany)
10:00 - 10:30		Water networks in drug design L. Frye (Schrodinger, Portland, United States)
10:30 - 11:00		Coffee Break
11:00 - 11:15	P235	Designed covalent inhibitors of LRRK2 kinase mutants linked to familial Parkinson's disease S. Ray (Schrödinger LLC, Cambridge, United States)
11:15 - 11:30	P166	PQR309: A potent, brain-penetrant, dual Pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability F. Beaufils (PIQR Therapeutics AG, Basel, Switzerland)
11:30 - 12:00		The JECL and the HDB: A new HTS library and a triage system for drug discovery at the European Lead Factory A. Pannifer (University of Dundee, Dundee, United Kingdom)
		Vendor Exhibition, Hall 4.1
10:00 - 17:00		Vendor and Poster Exhibition



Scientific Programme

12:30 - 13:30

Industry Symposium, Room 1

Industry Symposium: Czech Centres of Excellence at a Glance - R&D and Partnering Opportunities

The Czech Republic is bringing its top research institutes to Basel to show why the country is embracing global partnerships in becoming once again one of leading centers for medical and pharmaceutical research and manufacture. As a country that laid down the principal laws of heredity, introduced the contact lens to the world and successfully developed the compounds on which current anti-AIDS drugs are based, the Czech Republic's research institutes are now partnering the world's best pharma companies to create the next generation of healthcare.

We have invited the Masaryk Memorial Cancer Institute that has over 80 years history of cancer research and clinical treatment, as well as ICRC that partners with Mayo Clinic in cardiovascular diseases and neuroscience.

There will be also IOCB that gave the world antiviral compounds used now by Gilead Sciences for the treatment of HIV and Hepatitis B, Apigenex that performs pharmaceutical research for global pharma companies and BIOCEV - the newly established joint center of the Czech Academy of Science and Charles University in Prague for biomedical and biotechnology research.

We will be presenting how our extensive research capacity can help other global pharma companies join in this rapidly developing programme of partnership.

The event is sponsored by the Czech Embassy in Switzerland and CzechInvest - Investment and Business Development Agency of the Czech Government

12:30 - 13:30

Czech Centres of Excellence at a Glance - R&D and Partnering Opportunities

K. Borůvka (Ambassador - Czech Embassy, Berne, Switzerland)

M. Kořínek (Apigenex, Prague, Czech Republic)

V. Král (BIOCEV, Prague, Czech Republic)

P. Ryšávková (FNUSA-ICRC, Brno, Czech Republic)

R. Demlová (Masaryk Memorial Cancer Institute, Brno, Czech Republic)

J. Zahrádka (IOCB - Institute of Organic Chemistry and Biochemistry, Prague, Czech Republic)



Scientific Programme

12:30 - 13:30

Industry Symposium, Room 2

Industry Symposium: Cell Therapies Catapult

“Cell Therapies – the Catapult Approach to Successful Translation”

With novel cell-based therapies starting to reach the clinic to address unmet medical needs, there is an growing requirement for translational expertise.

The Cell Therapy Catapult was established by the UK government in 2012 as a centre for excellence to bridge the gap between scientific research and full scale commercialisation, and to accelerate the growth of the industry.

Its expert teams are built around the barriers to translation, namely:

- Business Development including business models and health economics;
- Regulatory including pre-clinical and clinical planning, and
- Manufacturing including assay and process development for large scale cell production.

These teams work with global partners from the entire breadth of the industry, learning from each other, developing broadly applicable solutions, and thus enabling the commercial development of clinical applications.

Meet us in Basel to find out how you can collaborate with us on your early stage project, or how you can access our expertise for your commercial development.

The event is kindly sponsored by the UK Science and Innovation Network in Switzerland.

12:30 - 13:30

Industry Symposium, Room 3

Industry Symposium: From iPS cells to hepatocytes: Cellartis® Enhanced hiPS-HEP in Toxicity Applications and the Cellartis iPS Cell to Hepatocyte Differentiation System

Learn about Cellartis Enhanced hiPS-HEP, including hepatic characterization, Cytochrome P450 function, and performance in toxicity applications. Generate your own functional hiPS-derived hepatocytes using the Cellartis iPS Cells to Hepatocytes Differentiation System.



Scientific Programme

12:30 - 13:30

Industry Symposium, Room 4

Industry Symposium: Multi-Dimensional High-Throughput Screening with the New ImageXpres Micro Confocal High-Content Imaging System

In recent years there have been great advances in the adoption of automated microscopy to drive more predictive, physiologically relevant cell-based assays for drug discovery, as well as for assessing the toxicity of chemical compounds, drug candidates and environmental agents. There is an increasing interest in using three-dimensional (3D) spheroids for modeling cancer and tissue biology, with the goal of improving the ability of those assays to fail unsuitable compounds earlier in the discovery process and to drive promising drug candidates forward. Next-generation high-content, high-throughput tools for microscopy offer innovative and automated techniques for evaluating this complex biology.

During this symposium, you will learn how the latest advances in our confocal high-content imaging technologies will help you tackle:

- Drug screening of 3D cancer and hepatocyte spheroids
- Assessing dose-dependent effects of several neurotoxic chemicals on autophagy and mitophagy in iPSC-derived neurons and PC12 cells
- Screening surface binding molecules in no-wash homogeneous assays with high background

Explore new biology with the introduction of our new ImageXpress® Micro Confocal High-Content Imaging System. Its revolutionary optical design gives you crisp confocal images that are easily quantified. With the throughput in confocal mode that you'd expect from widefield screening systems, you will finally be able to run assays using complex cell models like spheroids with more quantitative and statistically relevant results. This exciting new technology re-enforces Molecular Devices' continuous commitment to helping you streamline your research.

12:30 - 13:30

Multi-Dimensional High-Throughput Screening with the New ImageXpres Micro Confocal High-Content Imaging System

G. Chandy (Molecular Devices, Sunnyvale, United States)
C. Holz (Molecular Devices, Berlin, Germany)

13:30 - 14:15

Keynote, Room 5

Keynote Lecture 2 - J. Reed, Roche

13:30 - 13:40

Transforming science into medicine

J. Reed (F. Hoffmann-La Roche, Basel, Switzerland)

14:15 - 17:30

Scientific Forum, Room 4

GPCR

R. Bouhelal (Novartis Pharma AG, Basel, Switzerland)
X. Leroy (Actelion Pharmaceuticals Ltd., Allschwil, Switzerland)

14:15 - 14:30

Introduction to the Forum

R. Bouhelal (Novartis Pharma AG, Basel, Switzerland)
X. Leroy (Actelion Pharmaceuticals Ltd., Allschwil, Switzerland)



Scientific Programme

- 14:30 - 15:00** **Disease modulation of GPCR oligomer expression in the brain**
F. Ciruela (University of Barcelona, Barcelona, Spain)
- 15:00 - 15:30** **Towards the development of a PET radioligand for the in vivo imaging of cannabinoid receptor subtype 2 (CB2)**
S. Ametamey (ETH Zurich, Zurich, Switzerland)
- 15:30 - 16:00** **Coffee Break**
- 16:00 - 16:30** **G protein-coupled receptor structures and their implications for structure-based drug discovery**
V.-P. Jaakola (Novartis Pharma AG, Basel, Switzerland)
- 16:30 - 17:00** **Structure Based Drug Discovery with Stabilised G Protein-Coupled Receptors**
C. Fiez-Vandal (Heptares Therapeutics, Welwyn Garden City, United Kingdom)
- 17:00 - 17:15** **P197 Label free technologies to study interactions of human adenosine A2A receptor in detergent and membrane environment**
S. Huber (F. Hoffmann - La Roche, Basel, Switzerland)
- 17:15 - 17:30** **P194 Activation of G-protein-coupled receptors correlates with the formation of a continuous internal water pathway**
S. Yuan (Actelion Pharmaceutical Company, Allschwil, Switzerland)
- Scientific Forum, Room 1
- 14:30 - 17:00** **Peptide Therapeutics**
T. Vorherr (Novartis Pharma AG, Basel, Switzerland)
E. Kitas (Roche Innovation Center, Basel, Switzerland)
R. Stocklin (Atheris SA, Geneva, Switzerland)
- 14:30 - 15:00** **Dalazatide, a first-in-class blocker of the Kv1.3 potassium channel on effector memory T cells: safety, tolerability and proof of concept immunomodulation in patients with active plaque psoriasis**
S. Iadonato (Kineta Inc., Seattle, United States)
- 15:00 - 15:30** **ARG011 a clinical candidate for the buccal delivery of Exenatide using ArisCrown Technology**
P. Botti (Arisgen, Geneva, Switzerland)
- 15:30 - 16:00** **Coffee Break**
- 16:00 - 16:30** **A breakthrough technology for sublingual delivery of peptides, proteins and immune-therapies**
Y. Decadt (Biologus, Hergiswil, Switzerland)
- 16:30 - 17:00** **Biophysical characterization of lipidated peptides and its interaction with serum albumin**
S. Kanai (F. Hoffmann-La Roche, Basel, Switzerland)



Scientific Programme

- Scientific Forum, Room 2
- 14:30 - 17:00** **Stem Cells in Biomedicine**
 R. Heilker (Boehringer Ingelheim, Biberach, Germany)
 C. Cusulin (Roche Innovation Center, Basel, Switzerland)
 C. Hippert (Roche Innovation Center, Basel, Switzerland)
- 14:30 - 15:00** **Key challenges in stem cell-based therapy in diabetes**
 H. Semb (University of Copenhagen, Copenhagen, Denmark)
- 15:00 - 15:30** **Bioengineering stem cell-based organoid models**
 M. Lutolf (EPFL, Lausanne, Switzerland)
- 15:30 - 16:00** **Long-term single cell quantification: new tools for old questions**
 T. Schroeder (ETH Zurich, Zurich, Switzerland)
- 16:00 - 16:30** **Coffee Break**
- 16:30 - 17:00** **Implementing iPSC technology**
 B. Anson (Cellular Dynamics International, Madison, United States)
- Scientific Forum, Room 3
- 14:30 - 16:00** **Medicinal Chemistry**
 J. Harris (cjh consultants, Eynsford, United Kingdom)
 A. Hersey (EMBL-EBI, Hinxton, United Kingdom)
- 14:30 - 15:15** **The interplay of practical and informatics aspects of drug repositioning**
 J.P. Overington (Stratified Medical, London, United Kingdom)
- 15:15 - 16:00** **Unbiased in-vivo phenotypic screening: Discovery of drugs treating type II diabetes and Parkinson's dyskinesia**
 C. Lipinski (Melior Discovery, Exton, United States)
- Scientific Forum, Room 5
- 14:30 - 17:00** **Next Generation Sequencing**
 C. Mason (Cornell University, New York, United States)
 J. Dudley (Icahn School of Medicine at Mount Sinai, New York, United States)
 B. Bhullar (Novartis Pharma AG, Basel, Switzerland)
- 14:30 - 15:00** **Reaching the holy grail of biogeography - from genome to home village**
 E. Elhaik (University of Sheffield, Sheffield, United Kingdom)
- 15:00 - 15:30** **The Targeted Locus Amplification (TLA) Technology for targeted complete NGS sequencing & haplotyping.**
 M. van Min (Cergentis, Utrecht, Netherlands)
- 15:30 - 16:00** **Coffee Break**



Scientific Programme

16:00 - 16:30 **Development of a quantitative targeted RNA-Seq methodology for use in differential gene expression analysis**
V. Devgan (Qiagen Sciences, Frederick, United States)

16:30 - 16:40 **Impact of reproducibility in cell-based drug screening for biomarker development**
B. Haibe-Kains (Princess Margaret Cancer Centre, Toronto, Canada)

Interactive Poster Session, Hall 4.1 - Coffee 2

Interactive Poster Session & Apéro

- P100** **HTSfor muscarinic cholinergic receptors antagonists**
V. Tonkopi (Institute of Limnology, St.Petersburg, Russian Federation)
- P102** **dragonfly: an ideal solution to problematic liquids in screening environments**
J. Jenkins (TTP Labtech, Royston, United Kingdom)
- P103** **Identifying a protein biomarker in blood applying an unbiased data-driven approach**
F. Staubli (Nebion AG, Zürich, Switzerland)
- P104** **Miniaturized serial dilution of compounds: essential for ultrahigh throughput screening (uHTS) drug discovery**
J. Jenkins (TTP Labtech, Royston, United Kingdom)
- P105** **Verifying the accuracy and precision of liquid handlers is essential for assay reliability**
J. Jenkins (TTP Labtech, Royston, United Kingdom)
- P106** **Fluorescence and docking studies on the binding of copper and cobalt complexes to DNA and RNA**
Y. Thakur (Pt. Ravishankar Shukla University, Raipur, India)
- P109** **An in silico high binding free energy affinity value prediction of a novel hyper-multi-targeted computer-aided CREKA/YIGSR-peptide mimotopic dual Inhibitor against tumor growth, metastasis related glioblastoma conserved motif-like peptide domains**
I. Grigoriadis (Biogenea Pharmaceuticals Ltd, Thessaloniki, Greece)
- P112** **Evaluation of neuropharmacological activities of aqueous root-extracts of ficus benghalensis in Swiss albino mice**
G.P. Rauniar (B.P. Koirala Institute of Health Sciences, Dharan, Nepal)
- P117** **Lead identification and computer-aided molecular optimization of novel collagenase inhibitors consisting of a recored VAAHE/PRCGNPD peptidomimic highthroughput screened pharmacophore features to matrix contributing of disease arthritis states**
I. Grigoriadis (Biogenea Pharmaceuticals Ltd, Thessaloniki, Greece)
- P118** **An integrated solution to provide phenotypic primary and secondary screening of a full deck compound library**
J. Graystone (TTP Labtech, Royston, United Kingdom)
- P120** **Rapid analysis of 3D tumour cultures in soft agar and on ultra-low attachment plates using a laser scanning imaging system**
J. Graystone (TTP Labtech, Royston, United Kingdom)



Scientific Programme

- P125** **Molecular docking of natural FTase inhibitors: effect of substrate on binding interactions**
H.N. Moorthy (University of Porto, Porto, Portugal)
- P126** **An in silico chemoproteomic prediction-scan for the generation of a tyrosinase aa95-104FMGFNCGNCK antigenic patternLFA-3/IgG fusion polypeptide IleAlaArgArgPheLeuOH (Kinetensin) mimetic pharmacophore on conserved Vitiligo post-transcripts domains**
N. Grigoriadis (Biogenea SA, Thessaloniki, Greece)
- P128** **An approach to control purity of the drug substance for non-clinical study**
Y. Okubo (Toyama Chemical Co., Ltd., Toyama-shi, Japan)
- P129** **A compound derived from Psoralea glandulosa L. is a novel inhibitor of Toll-like receptor 7**
N. Okamoto (Univ. Toyama, Toyama, Japan)
- P130** **Combination of flow cytometry-based phenotypic screening and smart compound selection for rapid identification of novel cell cycle inhibitors**
L. Brault (Exquiron Biotech AG, Reinach, Switzerland)
- P131** **Solutions for screening epi-reader protein - protein interactions - the FLEXYTE® fluorescence lifetime assay platform**
G. Cotton (Almac, Edinburgh, United Kingdom)
- P132** **In-silico research to discover new inhibitors for matrix protein VP 40 from Ebola virus: virtual screening, molecular docking & ADMET study**
A.B. Ismail (Cyberjaya University College of Medical Science, Cyberjaya, Malaysia)
- P133** **The development of fluorescence lifetime technologies as an enabling assay platform for a variety of target classes**
G. Cotton (Almac, Edinburgh, United Kingdom)
- P134** **Alpha-amylase inhibitory effects of Kribbella sp. UTM 522 and Streptomyces sp. UTM 2301 culture broth extracts**
J. Hamedi (University of Tehran, Tehran, Iran, Islamic Republic of)
- P135** **Increased SPR-sensitivity enables reliable fragment screening and kinetic characterization at lower surface densities**
U.W. Roder (GE Healthcare Europe GmbH, Freiburg, Germany)
- P136** **Affinity measurement of antibodies in allergy diagnosis**
C. Schuhmacher (HORIBA Jobin Yvon GmbH, Unterhaching, Germany)
- P137** **Use of fluorescence lifetime as a confirmation screen for FRET primary screens**
W. Bowen (TTP Labtech, Royston, United Kingdom)
- P138** **Computational evaluation of novel natural inhibitors for class IIa histone deacetylase (HDAC) towards Spinocerebellar ataxia**
S. Sinha (TERI University, New Delhi, India)
- P139** **Detection and identification of non-covalent interactions with SPRI-MALDI MS**
C. Schuhmacher (HORIBA Jobin Yvon GmbH, Unterhaching, Germany)
- P140** **High fidelity small molecule DNA-encoded yoctoreactor libraries**
L.K. Petersen (Vipergen ApS, Copenhagen, Denmark)



Scientific Programme

- P141** **Monitoring cell health in real-time and in 3D**
R. Edward (BioStatus Limited, Shepshed, United Kingdom)
- P142** **SiMPLInext: the next generation of well-plate inserts for predictive model of biological barriers**
P. Tarbouriech (CSEM SA, Neuchâtel, Switzerland)
- P143** **Induction of apoptosis in human alveolar adenocarcinoma cell line by Streptomyces sp. UTM 676**
J. Hamedi (University of Tehran, Tehran, Iran, Islamic Republic of)
- P144** **Optogenetics applied to the High Throughput Screening: novel cellular assays controlled by light.**
S. Corazza (Axxam S.p.A, Bresso, Italy)
- P145** **Target characterization of a novel chlamydocin derivative**
C.N. Parker (Novartis, Basel, Switzerland)
- P146** **Recombinant anti-idiotypic antibodies for antibody drug development**
F. Ylera (Bio-Rad AbD Serotec GmbH, Puchheim, Germany)
- P148** **How do HTRF® epigenetic binding domain assays perform compared to other technologies?**
T. Roux (Cisbio Bioassays, Codolet, France)
- P149** **Universal HTRF® phospho-protein platform: from 2D, 3D, primary cells to patient derived tumor cells**
J. Vallaghe (Cisbio Bioassays, Codolet, France)
- P150** **Binding studies of type I, II, and III kinase inhibitors against Bcr-Abl kinase using back-scattering interferometry: a tale of allostery**
R.R. Lavieri (Molecular Sensing Inc., Los Gatos, United States)
- P151** **A rational approach for the discovery of inhibitors of NSD2 for the treatment of cancer**
X. Espanel (Inventiva, Dijon, France)
- P152** **Synthesis of novel-s-substituted aminoalkyl aminoethyl sulfide, sulfoxide as potential antidotes against sulfur mustard toxicity**
V.K. Mishra (Dr. Harisingh Gour University, Sagar, India)
- P153** **Synthesis of some novel bioactives 3-[5-substituted 1,3,4-thiadiazole -2 YL]-2- styryl quinazoline-4(3H)-ones as potential anticonvulsant compounds**
V.K. Mishra (Dr. Harisingh Gour University, Sagar, India)
- P154** **Target and biomarker identification platform to design new drugs against aging and age-related diseases**
P. Fedichev (Gero Limited, Hong Kong, Hong Kong)
- P155** **Antibody based targeting of beta-amyloid fragment fingerprints during early peptide oligomerization. A novel diagnostic and therapeutic tool for prodromal Alzheimer's disease?**
A.W. Schmid (Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland)
- P156** **Effect of Jobelyn® on memory impairment induced by unpredictable chronic mild stress in mice**
S. Umukoro (University of Ibadan, Ibadan, Nigeria)



Scientific Programme

- P157 Screening anti-aging interventions for fun and profit**
K.G. Morse Jr. (none, Bellingham, United States)
- P158 Extracellular deposits of beta-amyloid in the transgenic mouse model of Alzheimers disease**
H. Omid (Azad University of Tehran, Olom Tahghyghat, Tehran, Iran, Islamic Republic of)
- P161 Targeting FAK using inhibitors of protein-protein interactions**
P. Rondé (University of Strasbourg, CNRS UMR 7213, Illkirch, France)
- P162 Multi-step clustering of data on a multi-target effect of a combination phytomedicine, STW 5**
O. Kelber (Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany)
- P163 Tetraiodothyroacetic acid-conjugated polyethylenimine for enhanced delivery of plasmid DNA via integrin receptor**
A. Dehshahri (Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic of)
- P164 Modified polyamidoamine based nanoparticles for tumor cell gene delivery**
S. Hossaini Alhashemi (Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic of)
- P165 The acetogenin-based bis-tetrahydropyran 1,4-triazole, JM425 is trypanocidal through inhibition of mitochondrial complex V**
L.B. Tulloch (University of St Andrews, St Andrews, United Kingdom)
- P166 PQR309: A potent, brain-penetrant, dual Pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability**
F. Beauflis (PIQUR Therapeutics AG, Basel, Switzerland)
- P167 Synthesis and evaluation of some newer hybrids of diclofenac acid and 1, 3, 4-oxadiazole: reduction of ulceration with anti-inflammatory activity**
R. Yadav (Banasthali University, Banasthali, India)
- P168 Immediate drop on demand technology - a new technology for cell dispensing in a nanoliter range**
L. Schober (Fraunhofer Institute for Manufacturing Engineering and Automation IPA, Stuttgart, Germany)
- P169 Using sub-micron surface structures to eliminate enzymatic treatments in adherent cell passaging**
M. Liley (CSEM SA, Neuchâtel, Switzerland)
- P170 Improvement of mechanical properties of 3D printed hydroxyapatite scaffolds by culture of osteoblast-like cells under perfusion flow**
N. Rimmer (School of Life Sciences FHNW, Muttenz, Switzerland)
- P171 Microscale hydrogel patterning to manipulate stem cell fate**
L. Kolb (École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland)
- P172 Comparison of differentiation potential of male mouse adipose tissue and bone marrow derived-mesenchymal stem cells into germ cells**
P. Pasbakhsh (Tehran University of Medical Sciences/Medical School, Tehran, Iran, Islamic Republic of)
- P173 Miniaturisation technologies for cost effective library preparations for next-generation sequencing (NGS)**
J. Jenkins (TTP Labtech, Royston, United Kingdom)



Scientific Programme

- P174** **Single-cell resolution of emergent clones in the myelodysplastic syndromes during therapy and disease progression**
P. Vijay (Weill Cornell Medical College, New York, United States)
- P175** **Analysis of RNA editing in non-human primates**
M. Bozinovski (Weill Cornell Medical College, New York, United States)
- P176** **Quality control assessment and clinical application of nanopore sequencing**
N. Alexander (Weill Cornell Medical College, New York, United States)
- P177** **Benchmarking and standardization of structural variation detection methods**
E. Henaff (Weill Cornell Medical College, New York, United States)
- P178** **Epigenome interactions In complex neurogenetic disorders**
D. Chandramohan (Weill-Cornell Graduate School, New York, United States)
- P179** **Pre-implantation genetic screening using semiconductor high-throughput sequencing**
N.V. Aleksandrova (Federal State Institution 'Research Center for Obstetrics, Gynecology and Perinatology', Moscow, Russian Federation)
- P180** **Quantification of the cytochrome P450 enzyme system - rapid screening of CYP induction by TXP-immunoaffinity mass spectrometry**
O. Poetz (NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany)
- P181** **Circulating microRNA profiles in human drug-induced liver injury**
E. Lader (QIAGEN Sciences, Frederick, United States)
- P182** **Neuroprotective properties of *Melissa officinalis* after hypoxic-ischemic injury both in vitro and in vivo**
G. Hassanzadeh (Tehran University of Medical Sciences/Medical School, Tehran, Iran, Islamic Republic of)
- P183** **The enhancement of peptide drugs entrapped in nanovesicles**
T. Panyosak (School of Pharmaceutical Sciences, University of Phayao, Muang Phayao, Thailand)
- P184** **Presence of polyketide synthases and peptide synthetases genes in the bacteria isolated from intertidal gastropods of Portugal coast**
P. Vijaya (CIIMAR, Porto, Portugal)
- P185** **Mechanisms of action in gastroenterology: comparison of a prokinetic drug and a herbal medicine**
O. Kelber (Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany)
- P186** **Adenosine receptors as a target in colonic inflammation**
K. Nieber (Institute for Pharmacy, Leipzig University, Leipzig, Germany)
- P187** **Purification of circulating cell-free DNA from plasma using the automated large-volume extraction on the QIASymphony SP instrument**
M. Frietsch (QIAGEN, Hombrechtikon, Switzerland)
- P188** **Establishment of the culture condition to maintain the primary human colorectal cancer microenvironment by using a 3D perfusion bioreactor**
C. Manfredonia (University Hospital of Basel, Basel, Switzerland)



Scientific Programme

- P189** **The correlation of diastolic dysfunction with TIMI frame count in patients with chronic stable angina pectoris**
N. Omidi (Tehran University of Medical Sciences/Zyaeean Hospital, Tehran, Iran, Islamic Republic of)
- P191** **Didepsid atranorin shows selective cytotoxic effect on flatworm *Mesocostoides vogae* in vitro and in vivo whereas exerting immunomodulatory and protective effects in vivo in experimental mouse infection**
G. Hřčkova (Institute of Parasitology of SAS, Kořice, Slovakia)
- P192** **Genomic sequence analysis of *Mycobacterium tuberculosis* H37Rv and *M. tuberculosis* DR-689 subjected to 200 continuous subcultures**
L. Vera-Cabrera (Universidad Autonoma de Nuevo Leon, Monterrey, Mexico)
- P193** **Sodium chloride induced aggregation of monoclonal antibodies at low pH: prevention by additives**
F. Bickel (Biberach University of Applied Science, Biberach, Germany)
- P194** **Activation of G-protein-coupled receptors correlates with the formation of a continuous internal water pathway**
S. Yuan (Actelion Pharmaceutical Company, Allschwil, Switzerland)
- P195** **Fluorescent ligand binding and internalization assays to identify and profile anti Formyl Receptor 1 (FPR1) antibodies**
P. Cariuk (MedImmune, Cambridge, United Kingdom)
- P196** **Fluorescence cross-correlation spectroscopy for the study of membrane proteins**
F. Becker (Intana Bioscience, Planegg, Germany)
- P197** **Label free technologies to study interactions of human adenosine A2A receptor in detergent and membrane environment**
S. Huber (F. Hoffmann - La Roche, Basel, Switzerland)
- P198** **Multicolor fluorescent biosensors for multiplexed detection of GPCR receptor activation**
C. Salado (INNOPROT, Derio, Spain)
- P199** **PI3K and DNA repair - point of convergence?**
K. Zmajkovicova (Universitat Basel, Basel, Switzerland)
- P200** **Screening of synergic interactions of anti-angiogenic and anti-tumor compounds**
M.Á. Medina (Universidad de Málaga, Málaga, Spain)
- P201** **Synergism research: a tool for the study of pharmacology and toxicology of herbal medicinal products**
O. Kelber (Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany)
- P202** **Gene expression profiling as a promising approach for justifying fixed drug combination products**
O. Kelber (Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany)
- P203** **St John´s wort: what is the key for the bioavailability of a phytomedicine active in mild to moderate depression?**
V. Butterweck (University of Applied Sciences Northwestern Switzerland, Muttenz, Switzerland)



Scientific Programme

- P204 Use of phase contrast imaging to track morphological cellular changes due to apoptotic activity**
B. Larson (BioTek Instruments, Inc., Winooski, United States)
- P205 Phenotypic and epigenetic mechanism of action determinations of histone methylase and demethylase inhibitors using digital widefield microscopy**
B. Larson (BioTek Instruments, Inc., Winooski, United States)
- P206 Combining kinetic ligand binding and 3D tumor invasion technologies to assess drug residence time and anti-metastatic effects of CXCR4 inhibitors**
B. Larson (BioTek Instruments, Inc., Winooski, United States)
- P207 Quantification of MMP activity and inhibition in a 3D tumor invasion model**
B. Larson (BioTek Instruments, Inc., Winooski, United States)
- P208 High-content assays for characterizing the viability and morphology of the 3D cancer spheroid cultures**
O. Sirenko (Molecular Devices, LLC, Sunnyvale, United States)
- P209 Fluorescence-based assay development to screen drugs against Parkinson´s disease**
C. Salado (INNOPROT, Derio, Spain)
- P210 Comprehensive profiling of signal transduction pathways in human tumours - bead-based Western blotting for characterising primary tumour tissue**
M.F. Templin (NMI an der Universität Tübingen, Reutlingen, Germany)
- P211 BKM120-mediated G2 Arrest: structural and functional segregation of off-target action and PI3K Inhibition**
T. Bohnacker (Universität Basel, Basel, Switzerland)
- P212 MicroRNA-497 suppresses tumorigenesis and induces apoptosis in human pancreatic cancer by targeting BCL-xl**
D. Li (Xi'an Jiaotong University Health Science Center, Xi'an, China)
- P213 Derivatives of benzopyrans are selective estrogen receptor beta agonists (SERBAs): molecular modeling study of benign prostatic hyperplasia**
S. Gopalakrishna (Karnatak University, Dharwad, India)
- P214 Different effects of rosiglitazone in rat glioma cells C6 and primary rat astrocytes**
E. Pankevich (Lomonosov Moscow State University, Moscow, Russian Federation)
- P215 Exploiting signaling dynamics to overcome the robustness of oncogenic networks**
R. Sri Ramaratnam (University of Basel, Basel, Switzerland)
- P216 Measuring Wnt-pathway activity in cancer models**
O. Poetz (NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany)
- P217 Dynamic visualisation of the PI3-kinase pathway**
V. Hurst (Dept. Biomedicine, University of Basel, Basel, Switzerland)
- P218 New cell-based HTRF® assays for the exploration of Wnt signaling pathway**
M. Romier (Cisbio Bioassays, Codolet, France)



Scientific Programme

- P219** **In vitro designer microenvironments for modeling the endothelin axis in ovarian cancer**
S.C. Rizzi (QGel SA, Lausanne, Switzerland)
- P220** **BMP-2 induces epithelial-to-mesenchymal transition and accelerates motility and invasiveness of breast cancer cells via depletion of pRb and up-regulation of CD44**
H. Peide (Jinan University, Guangzhou, China)
- P221** **Patient recruitment 2.0: become a partner in the patient journey using digital media**
C. Gossens (F. Hoffmann-LaRoche Ltd, Basel, Switzerland)
- P222** **Remote digital biomarker monitoring - bringing a smartphone-based diagnostic test for Parkinson's disease progression into an interventional trial**
C. Gossens (F. Hoffmann-LaRoche Ltd, Basel, Switzerland)

Interactive Poster Session, Hall 4.1 - Coffee 3

Interactive Late Breaker Poster Session & Apéro

- P224** **Native and stabilized membrane proteins for drug discovery: CALIXAR approach**
E. Mandon (CALIXAR, Lyon, France)
- P225** **Optogenetics: a bright future for voltage gated ion channels**
J.M. D'Angelo (Hamamatsu, Massy, France)
- P226** **Drug Discovery in space and under microgravity**
M. Aebi (SpacePharma SA, Delemont, Switzerland)
- P227** **An insight into the interaction of oxo-vanadium (V) complex with nucleic acid**
M. Tripathi (Pt. Ravishankar Shukla University, Raipur, India)
- P228** **Validation of a new optical method for ion channel screening**
F. Grohovaz (San Raffaele University, Milan, Italy)
- P229** **High throughput screening of genetically encoded substance libraries**
M. Held (ETH Zurich, Basel, Switzerland)
- P230** **Rapid monoclonality verification methods to boost cell line development**
M. McPate (Molecular Devices, Wokingham, United Kingdom)
- P231** **Patch them all - fully HTS-compatible automated patch clamping of 384 cells at once for massively parallel ion channel screening**
I. Rinke (Nanion Technologies, Munich, Germany)
- P232** **BioMAP® human primary cell systems for improving drug discovery and development**
R. Price (DiscoverX Corporation, South San Francisco, United States)
- P233** **Secondary bioactive metabolic potential of Actinophytocola sp. UTMC1143**
F. Mohammadipanah (School of Biology, College of Science, University of Tehran, Tehran, Iran, Islamic Republic of)
- P234** **A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation**
A. Artemov (Insilico Medicine, Baltimore, United States)



Scientific Programme

- P235** **Designed covalent inhibitors of LRRK2 kinase mutants linked to familial Parkinson´s disease**
S. Ray (Schrödinger LLC, Cambridge, United States)
- P236** **The protective effect of Borago Officinalis extract on amyloid β (25-35)-induced long term potentiation disruption in the dentate gyrus of male rats**
M. Mehdizadeh (Cellular and Molecular Research Center, Faculty of Advance Technologies in Medicine, Department of Anatomy, Iran University of Medical Sciences, Tehran, Iran, Islamic Republic of)
- P237** **Novel BET bromodomain inhibitors for cardiovascular and inflammatory diseases**
H. Kempen (Dybly AG, Basel, Switzerland)
- P238** **Neuronal Shc: Synaptic modulator affecting neuro-plasticity and neuro-protection**
N. Mori (Nagasaki University School of Medicine, Nagasaki, Japan)
- P240** **Psychosocial stress induces inflammation, altered expression of neuron and glia transcriptomes and CNS connectivity, and disrupted emotionality in adult mice**
C. Pryce (University of Zurich, Zurich, Switzerland)
- P241** **Adenosine A1 and A2A receptors as possible biomarker in peripheral cells from idiopathic normal-pressure hydrocephalus patients**
B. Arosio (University of Milan, IRCCS Ospedale Maggiore Policlinico, Milan, Italy)
- P242** **Using signaling pathway activation analysis to identify prospective drugs that may slow down or reverse the effects of skin aging and photo-aging**
P. Mamoshina (InSilico Medicine, Inc, Baltimore, United States)
- P243** **Identification of differentially expressed micro- and mRNA clusters in blood of patients with coronary artery disease: intersection with calcification pathways and implications in cardiovascular diseases**
G. Mkrtchyan (Lomonosov Moscow State University, Moscow, Russian Federation)
- P244** **Age-related macular degeneration and Hutchinson-Gilford progeria diseases as a proof that the aging should be considered as a disease**
E. Makarev (Atlas Regeneration, Winston Salem, United States)
- P245** **GeroScope, a novel method for in silico screening of candidate geroprotective drugs. Application of predicted compounds to reverse replicative senescence in fibroblasts**
A. Aliper (InSilico Medicine, Inc, ETC, Johns Hopkins University, Baltimore, United States)
- P246** **iScienceSearch - the Internet search engine for chemists & biologists**
A. Kos (AKos GmbH, Steinen, Germany)
- P247** **Development of models to predict melting and pyrolysis point data with 300k compounds mined from the patents data**
I. Tetko (Helmholtz Zentrum Muenchen, Neuherberg, Germany)
- P248** **A novel, microstructured, polymer-based metal enhance fluorescence (MEF) substrate using established industrial molding and coating processes derived from Blu-ray disc manufacturing for the use in ultra-sensitive fluorescence immunoassays**
G. Hawa (FIANOSTICS GmbH, Wr. Neustadt, Austria)
- P249** **Sensitive mutation detection by sequencing circulating cell-free DNA**
N. Fang (QIAGEN GmbH, Hilden, Germany)



Scientific Programme

- P250 Use of high throughput electric field stimulation (EFS) coupled with intracellular Ca²⁺ kinetics measurements on iPSC-derived cardiomyocytes**
J.M. D'Angelo (Hamamatsu, Massy, France)
- P251 In vivo and in vitro models of bromodomain and extraterminal domain inhibitor-induced intestinal stem cell loss and villous atrophy reveal differential human vs pre-clinal species sensitivity**
P. Newham (AstraZeneca, Cambridge, United Kingdom)
- P252 Integrating gene synthesis and microfluidics for rapid protein engineering**
M.C. Blackburn (Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland)
- P253 Ultrasensitive measurement of mutant Huntingtin in human CSF and rodent samples**
V. Fodale (IRBM Science Park, Pomezia, Italy)
- P255 Baculovirus expression vectors for optimal recombinant protein and virus-like particle production**
A.C. Chambers (Oxford Expression Technologies, Oxford, United Kingdom)
- P256 Rapid analysis and quantification of proteins in high throughput using PAIA assays**
C. Wosnitza (PAIA Biotech GmbH, Cologne, Germany)
- P257 BRET2 assay using the FDSS/ μ CELL: monitoring cell surface-receptor internalization and intracellular trafficking**
J.M. D'Angelo (Hamamatsu, Massy, France)
- P258 JAYCE technology to decipher receptor biology and pharmacology**
M. Kiry (Actelion Pharmaceuticals Ltd., Allschwil, Switzerland)
- P259 Increased production of antioxidants in the presence of cadmium by Promicromonospora sp. UTMC2243**
M. Mirjalili (University of Tehran, Tehran, Iran, Islamic Republic of)
- P260 Evaluation of combination treatment efficacy utilizing the Labcyte Echo® liquid handler and Echo® combination screen software with reduced cost, increased throughput and flexibility in an MCF-7 viability assay**
L. Orren (Labcyte, Sunnyvale, United States)
- P261 IncuCyte™ Chemotaxis System: a new and enabling solution for directional migration assays**
L. Gedge (Essen BioScience, Welwyn Garden City, United Kingdom)
- P262 Electric field stimulation (EFS) of human iPSC-derived neuron using Hamamatsu FDSS/ μ CELL**
J.M. D'Angelo (Hamamatsu, Massy, France)
- P263 Profiling of a compound library biased toward immunomodulating agents: multiplexed measurements of cell phenotype, viability, and cytokine secretion of human PBMCs**
S.P. Parel (Exquiron Biotech AG, Reinach, Switzerland)
- P264 High throughput screen for developmental neurotoxicity using human induced pluripotent stem cell-derived neurons**
O. Sirenko (Molecular Devices, LLC, Sunnyvale, United States)



Scientific Programme

Thursday, 24 September 2015

		Scientific Forum, Room 1
08:30 - 12:00		Aging and Drug Discovery A. Zhavoronkov (Insilico Medicine, Baltimore, United States) B. Bhullar (Novartis Pharma AG, Basel, Switzerland)
08:30 - 09:00		Intro B. Bhullar (Novartis Pharma AG, Basel, Switzerland)
09:00 - 09:30		Biology of aging 1985 to 2015: are we ready for clinical interventions? G. Martin (University of Washington School of Medicine, Seattle, United States)
09:30 - 10:00		Drugs that forestall aging - extending healthspan B. Kennedy (Buck Institute for Research on Aging, Novato, United States)
10:00 - 10:30		Coffee Break
10:30 - 11:00		Title to be Confirmed J. Campisi (Buck Institute for Research on Aging, Novato, United States)
11:00 - 11:30		Putative targets for extending lifespan and healthspan in mice G. Fuellen (Rostock University Medical Center, Rostock, Germany)
11:30 - 12:00	P154	Target and biomarker identification platform to design new drugs against aging and age-related diseases P. Fedichev (Gero Limited, Hong Kong, Hong Kong)
		Scientific Forum, Room 2
08:30 - 12:00		Translational Medicine P. Groenen (Actelion Pharmaceuticals Ltd., Allschwil, Switzerland) O. Peter (Actelion Pharmaceuticals Ltd., Allschwil, Switzerland) J. Mosbacher (Roche Innovation Center, Basel, Switzerland)
08:30 - 09:30		The healthcare ecosystem in 2050: How do we prepare? B. Munos (InnoThink Center for Research in Biomedical Innovation, Santa Monica, United States)
09:30 - 10:00		Roche personalized medicine: a vision turns into reality G. Maass (F. Hoffmann-La Roche, Grenzach-Whylen, Germany)
10:00 - 10:30		Coffee Break
10:30 - 11:00		Precision Medicine: From concepts to concrete cases E. Gosber (PatientsLikeMe, Cambridge, United Kingdom)
11:00 - 11:30		Swiss Personalized Health Initiative P. Meier-Abt (Swiss Academy of Medical Sciences, Basel, Switzerland)



Scientific Programme

11:30 - 12:00		<p>Personalized Healthcare and the Stakeholders C. Koelsch (Frankfurt, Germany)</p>
Scientific Forum, Room 4		
08:30 - 12:10		<p>GPCR R. Bouhelal (Novartis Pharma AG, Basel, Switzerland) X. Leroy (Actelion Pharmaceuticals Ltd., Allschwil, Switzerland)</p>
08:30 - 09:00		<p>Matching orphan ligands to membrane receptors F. Bassilana (Novartis Pharma AG, Basel, Switzerland)</p>
09:00 - 09:30		<p>Biased agonism: consequences for clinical candidates C. Cowan (Trevena Inc., King of Prussia, United States)</p>
09:30 - 10:00		Coffee Break
10:00 - 10:30		<p>Brain penetrating FPR2/ALXR agonists O. Corminboeuf (Actelion Pharmaceuticals Ltd, Allschwil, Switzerland)</p>
10:30 - 11:00		<p>Elucidation of the interactome of G protein coupled receptors in hypothalamic weight regulation H. Biebermann (Charité Medical Center Universitätsmedizin Berlin, Berlin, Germany)</p>
11:00 - 11:30		<p>Fluorescent biosensors for multicolored views of GPCR signaling. T. Hughes (Montana Molecular, Bozeman, United States)</p>
11:30 - 11:45	P186	<p>Adenosine receptors as a target in colonic inflammation K. Nieber (Institute for Pharmacy, Leipzig University, Leipzig, Germany)</p>
11:45 - 12:00		<p>Short Talk: Multicolor fluorescent biosensors for multiplexed detection of GPCR receptor activation I. Ramos (Innoprot S.L., Derio, Spain)</p>
12:00 - 12:10		<p>Concluding remarks R. Bouhelal (Novartis Pharma AG, Basel, Switzerland) X. Leroy (Actelion Pharmaceuticals Ltd., Allschwil, Switzerland)</p>
Scientific Forum, Room 5		
08:45 - 12:00		<p>Next Generation Sequencing C. Mason (Cornell University, New York, United States) J. Dudley (Icahn School of Medicine at Mount Sinai, New York, United States) B. Bhullar (Novartis Pharma AG, Basel, Switzerland)</p>
08:45 - 09:00		<p>Introduction J. Dudley (Icahn School of Medicine at Mount Sinai, New York, United States)</p>



Scientific Programme

09:00 - 09:30		Interpreting genome function by transcriptome analysis T. Lappalainen (New York Genome Center, New York, United States)
09:30 - 10:00		Next Generation Thinking - Bridging the Gap in Targeted Sequencing R. Beneke (Agilent Technologies, Santa Clara, United States)
10:00 - 10:30		Coffee Break
10:30 - 11:00		The extreme microbiome project (XMP) and development of new tools and standards for metagenomics and microbiome applications S. Tighe (University of Vermont, Burlington, United States)
11:00 - 11:30		Targeted RNA Access panels for cancer and infectious diseases G. Schroth (Illumina, Hayward, United States)
11:30 - 12:00		Epigenomic studies for biomarker discovery in hematological malignancies M. Figueroa (University of Michigan Medical School, Ann Arbor, United States)
Scientific Forum, Room 3		
09:15 - 12:00		Medicinal Chemistry J. Harris (cjh consultants, Eynsford, United Kingdom) A. Hersey (EMBL-EBI, Hinxton, United Kingdom)
09:15 - 09:30		Introduction J. Harris (cjh consultants, Eynsford, United Kingdom) A. Hersey (EMBL-EBI, Hinxton, United Kingdom)
09:30 - 10:00		Open Data Sources for Drug Discovery A. Hersey (EMBL-EBI, Hinxton, United Kingdom)
10:00 - 10:30		Coffee Break
10:30 - 11:00		Enabling and supporting ubiquitin system drug discovery J. Mundin (Ubiquigent Ltd, Dundee, United Kingdom)
11:00 - 11:15	P165	The acetogenin-based bis-tetrahydropyran 1,4-triazole, JM425 is trypanocidal through inhibition of mitochondrial complex V L.B. Tulloch (University of St Andrews, St Andrews, United Kingdom)
11:15 - 11:30	P237	Novel BET bromodomain inhibitors for cardiovascular and inflammatory diseases H. Kempen (Dybly AG, Basel, Switzerland)
11:30 - 12:00		Chemoproteomic approaches for epigenetic drug targets G. Joberty (Cellzome GmbH, a GSK Company, Heidelberg, Germany)
Vendor Exhibition, Hall 4.1		
10:00 - 17:00		Vendor and Poster Exhibition



Scientific Programme

- Keynote, Room 5
- 13:30 - 14:15** **Keynote Lecture 3 - K. Asadullah, Charité**
- 13:30 - 13:40** **Trends in translation medicine: the value of external innovation**
K. Asadullah (Charité Medical Center, Berlin, Germany)
- Scientific Forum, Room 1
- 14:30 - 17:00** **Aging and Drug Discovery**
A. Zhavoronkov (Insilico Medicine, Baltimore, United States)
B. Bhullar (Novartis Pharma AG, Basel, Switzerland)
- 14:30 - 15:00** **In silico approaches to geroprotector screening**
A. Zhavoronkov (Insilico Medicine, Baltimore, United States)
- 15:00 - 15:30** **Criteria of aging-suppressive drugs**
A. Moskalev (Institute of Biology of Komi Science Center of RAS, Syktyvkar, Russian Federation)
- 15:30 - 16:00** **Coffee Break**
- 16:00 - 16:30** **AMPK and cellular aging in keratinocytes**
S. Jäger (L'Oreal, France)
- 16:30 - 17:00** **Title to be confirmed**
R. Hariri (Human Longevity, San Diego, United States)
- Scientific Forum, Room 2
- 14:30 - 16:00** **Translational Medicine**
P. Groenen (Actelion Pharmaceuticals Ltd., Allschwil, Switzerland)
O. Peter (Actelion Pharmaceuticals Ltd., Allschwil, Switzerland)
J. Mosbacher (Roche Innovation Center, Basel, Switzerland)
- 14:30 - 15:00** **MIDATA Personal Data Cooperatives - My Data Our Health**
E. Hafen (ETH Zurich, Zurich, Switzerland)
- 15:00 - 15:30** **Translational research and development of drugs: translatability assessment**
M. Wehling (University of Mannheim, Mannheim, Germany)
- 15:30 - 16:00** **RDoC: Integrating genetics, imaging, cognitive sciences to transform Mental Health diagnosis and treatment**
B. Cuthbert (National Institute of Mental Health NIMH, Rockville, United States)
- Oral Session - Best Abstracts, Room 3
- 14:30 - 17:15** **Oral and Poster Spotlight Session**



Scientific Programme

14:30 - 14:45	P220	<p>BMP-2 induces epithelial-to-mesenchymal transition and accelerates motility and invasiveness of breast cancer cells via depletion of pRb and up-regulation of CD44</p> <p>H. Peide (Jinan University, Guangzhou, China)</p>
14:45 - 15:00	P155	<p>Antibody based targeting of beta-amyloid fragment fingerprints during early peptide oligomerization. A novel diagnostic and therapeutic tool for prodromal Alzheimer´s disease?</p> <p>A.W. Schmid (Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland)</p>
15:00 - 15:15	P170	<p>Improvement of mechanical properties of 3D printed hydroxyapatite scaffolds by culture of osteoblast-like cells under perfusion flow</p> <p>N. Rimmer (School of Life Sciences FHNW, Muttensz, Switzerland)</p>
15:15 - 15:30	P171	<p>Microscale hydrogel patterning to manipulate stem cell fate</p> <p>L. Kolb (École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland)</p>
15:30 - 15:45	P161	<p>Targeting FAK using inhibitors of protein-protein interactions</p> <p>P. Rondé (University of Strasbourg, CNRS UMR 7213, Illkirch, France)</p>
15:45 - 16:00		Coffee Break
16:00 - 16:15	P252	<p>Integrating gene synthesis and microfluidics for rapid protein engineering</p> <p>M.C. Blackburn (Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland)</p>
16:15 - 16:30	P163	<p>Tetraiodothyroacetic acid-conjugated polyethylenimine for enhanced delivery of plasmid DNA via integrin receptor</p> <p>A. Dehshahri (Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic of)</p>
16:30 - 16:45	P240	<p>Psychosocial stress induces inflammation, altered expression of neuron and glia transcriptomes and CNS connectivity, and disrupted emotionality in adult mice</p> <p>C. Pryce (University of Zurich, Zurich, Switzerland)</p>
16:45 - 17:00	P174	<p>Single-cell resolution of emergent clones in the myelodysplastic syndromes during therapy and disease progression</p> <p>P. Vijay (Weill Cornell Medical College, New York, United States)</p>
17:00 - 17:15		Poster prize ceremony
Scientific Forum, Room 4		
14:30 - 17:30		<p>Signaling and Drug Resistance in Cancer</p> <p>A. Soltermann (University of Basel, Basel, Switzerland) M. Hall (University of Basel, Basel, Switzerland)</p>
14:30 - 15:00		<p>Targeting PI3K or microtubules - one Dalton to tip the balance</p> <p>M.P. Wymann (University of Basel, Basel, Switzerland)</p>



Scientific Programme

15:00 - 15:15	P210	<p>Comprehensive profiling of signal transduction pathways in human tumours - bead-based Western blotting for characterising primary tumour tissue</p> <p>M.F. Templin (NMI an der Universität Tübingen, Reutlingen, Germany)</p>
15:15 - 15:30	P217	<p>Dynamic visualisation of the PI3-kinase pathway</p> <p>V. Hurst (Dept. Biomedicine, University of Basel, Basel, Switzerland)</p>
15:30 - 16:00		Coffee Break
16:00 - 16:30		<p>Targeting metabolic symbiosis to overcome resistance to anti-angiogenic therapy</p> <p>G. Christofori (University of Basel, Basel, Switzerland)</p>
16:30 - 17:00		<p>Targeted cancer therapy and tumor heterogeneity: act locally, think globally</p> <p>M. Bentires-Alej (Friedrich Miescher Institute for Biomedical Research (FMI), Basel, Switzerland)</p>
17:00 - 17:30		<p>Mechanisms of evasive resistance in cancer</p> <p>M. Hall (University of Basel, Basel, Switzerland)</p>
14:30 - 17:00		<p>Scientific Forum, Room 5</p> <p>Next Generation Sequencing</p> <p>C. Mason (Cornell University, New York, United States) J. Dudley (Icahn School of Medicine at Mount Sinai, New York, United States) B. Bhullar (Novartis Pharma AG, Basel, Switzerland)</p>
14:30 - 15:00		<p>Analysing NGS data with clinical data in a translational medicine setting: tranSMART and cBioPortal</p> <p>C. van Bochove (The Hyve, Utrecht, Netherlands)</p>
15:00 - 15:30		<p>Bio-Linux: A FLOSS (Free/Libre Open Source) platform for genomic data analysis</p> <p>T. Travis (Bridge of Alford, United Kingdom)</p>
15:30 - 16:00		Coffee Break
16:00 - 16:30		<p>Whole genome sequencing in drug discovery research: a one fits all solution?</p> <p>M. Sultan (Novartis Institutes for Biomedical Research, Basel, Switzerland)</p>
16:30 - 17:00		<p>The Human Knockout Project: identifying loss of function variants in large population datasets</p> <p>K. Karczewski (Massachusetts General Hospital and The Broad Institute of Harvard and MIT, Boston, United States)</p>